Glycostem launches its new website

On the 2nd December Glycostem has officially launched its new website, which provides a comprehensive overview of our current position and ambitious plans on the application of NK cell immunotherapy in the treatment of cancer.

Read more >

Glycostem listed in independent article

November 2016;

Glycostem is delighted that we have been listed as the only not-public listed company in this article. If you are interested in the NK cell space, this is a recommended read.

Read more >

Orphan-Drug Designation request of NK Cell Product oNKord® granted by FDA

April 20, 2016
On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)

Management momentum in advance of pivotal trial

2018: Glycostem expands management team in expansion phase.

Read more >

Glycostem moves into new lab, production and HQ facility

March 2018;
Company now occupies new 500-square-meter space at Pivot Park.​

Read more >

Lupus Ventures takes stake in Glycostem

2018: Momentum continues to build in advance of Glycostem’s pivotal 2019 trials.

Read more >

Glycostem Clinical Data Recap

2018: Peer reviewed phase 1 trial

Please click here to open file.

Read more >

Eurostars Granted Project

2018: Eurostars Granted Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK

Please click here to open file.

MolMed and Glycostem Cooperation

June 2018: MolMed and Glycostem announce the execution of a binding term sheet for the development and manufacturing of allogeneic CAR-NK therapies.

Please click here to open file.

Subscribe to our newsletter